Angiotensin-converting enzyme inhibitors (ACE-Is) are an evidence-based treatment for
patients who after myocardial infarction (MI) present with either heart failure (HF) or left …

Angiotensin-converting enzyme (ACE) inhibitors have been shown to reduce both morbidity
and mortality in patients with chronic heart failure1 and in high-risk patients after acute …

Abstract Abstract Valsartan (Diovan®) is an oral angiotensin II-receptor antagonist with
specificity for the angiotensin II type 1 receptor subtype. It demonstrates antihypertensive …

Angiotensin-converting enzyme (ACE) inhibitors such as captopril reduce mortality and
cardiovascular morbidity among patients with myocardial infarction complicated by left …

Background Angiotensin-converting–enzyme (ACE) inhibitors such as captopril reduce
mortality and cardiovascular morbidity among patients with myocardial infarction …

Aim of study: Angiotensin‐converting enzyme (ACE) inhibitors prolong life, lower the
progression of heart failure, and decrease the need for hospitalizations in patients after …

Background Survivors of acute myocardial infarction (MI) complicated by heart failure and/or
resulting in left ventricular dysfunction are at heightened risk for subsequent death and …

Angiotensin converting enzyme (ACE) inhibitors are effective across the whole spectrum of
heart failure from mild to severe but there are little data on the use of ACE inhibitors …

Angiotensin-converting enzyme inhibitors (ACE inhibitors) have been shown to be effective
in improving symptoms and survival in patients with systolic left ventricular dysfunction …

ACE inhibitors have significantly decreased cardiovascular mortality, myocardial infarction
(MI), and hospitalizations for heart failure (HF) in patients with asymptomatic or symptomatic …